reports
- Kate Heseltine
Else Nutrition - Well funded for expansion
Else raised gross proceeds of C$7.35m through equity. It offered 7.004m units at C$1.05, with each unit consisting of one share and one warrant. The warrants have an exercise price of C$1.25 and an expiry date of June 2027. The company plans to use net proceeds of C$6.6m for sales and marketing and to build inventory as it expands into new geographies, and on research and development (R&D) as it continues to pursue its disruptive dairy- and soy-free infant formula. We leave our underlying foreca...
- Kate Heseltine
Else Nutrition - Formula for growth
Else Nutrition has a globally patented, 100% plant-based dairy- and soy-free formula, which offers a clean-label alternative for babies who are intolerant to dairy and soy and to families who are flexitarian or seeking more sustainable food options. It launched its toddler formula in August 2020 and successfully built sales infrastructure in the US during 2021, rolling out sales online and in-store. It has expanded by launching a nutritional drink for children and, more recently, a line of baby ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.